

# ForPatients

by Roche

## Healthy Volunteers

### A study to find out how safe is it to give people a new medicine for asthma (GDC-4379), and to see how this medicine is processed in the body

Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of inhaled GDC-4379 conducted in three parts: A single-ascending dose study in healthy volunteers, a multiple-ascending dose study in healthy volunteers, and a proof-of-activity study in patients with mild asthma

**Trial Status**  
Completed

**Trial Runs In**  
1 Countries

**Trial Identifier**  
GA41024

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

#### ***Trial Summary:***

Healthy volunteers for Parts A (  $n=48$ ) and B (  $n=32$ ), and asthma patients for Part C (  $n=48$ ) were enrolled at two study sites in New Zealand to evaluate the safety and tolerability of GDC-4379, an inhibitor of JAK1. Part A was a single-ascending dose study (1–80 mg of GDC-4379). Part B was a multiple-ascending dose study (3–80 mg QD). Part C was a proof of activity study (10–80 mg QD). Results showed GDC-0214 to be similarly tolerated in active and placebo dose groups. There were no deaths or serious side effects. One participant (Part B) stopped treatment due to a side effect. GDC-4379 showed some activity in reducing inflammation in patients with asthma. Based on this study, researchers decided not to develop GDC-4379 any further because the results showed that patients will need a very high dose of this medicine to control asthma.

**GA41024**  
Trial Identifiers

---

#### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
18 to 65 years

**Healthy Volunteers**  
Yes

---

This clinical trial was done to study a new medicine called, "GDC-4379", for the treatment of asthma. This study investigated whether it was safe to give people single and multiple

# ForPatients

*by Roche*

doses of GDC-4379. Researchers also wanted to find out what happened to GDC-4379 in the body, and if there was any indication that GDC-4379 may be useful in patients with asthma. One hundred and twenty-eight healthy people and patients with asthma took part in this study at two study centers in one country.